5 mg Filmtabletten
Sponsors
F. Hoffmann-La Roche AG, Verastem Inc., Goethe University Frankfurt
Conditions
ESTROGEN RECEPTOR-POSITIVEEndocrine-Sensitive phosphatidylinositol 3-kinase (PIK3CA)-MutatedEstrogen Receptor-PositiveHER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCERHER2-Negative Early Breast CancerHormone Receptor-PositiveInflammatory cardiovascular involvement due to COVID-19Metastatic breast cancer
Phase 1
Phase 2
Phase 3
A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-9545 COMBINED WITH PALBOCICLIB COMPARED WITH LETROZOLE COMBINED WITH PALBOCICLIB IN
PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER
Active, not recruitingCTIS2023-506911-16-00
Start: 2020-12-04Target: 259Updated: 2025-12-16
A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator’s Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP301)
RecruitingCTIS2023-508204-38-00
Start: 2024-07-02Target: 183Updated: 2026-01-06
Randomised placebo controlled clinical trial of efficacy of MYOcardial protection in postacute inFLAMmatory cardiac involvEment due to COVID-19 (MYOFLAME-19)
Active, not recruitingCTIS2024-516463-84-00
Start: 2022-12-13Target: 280Updated: 2025-04-25
A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared with Physician’s Choice of Adjuvant Endocrine Monotherapy in Patients with Estrogen Receptor-Positive, Her2-Negative Early Breast Cancer
Active, not recruitingCTIS2023-507172-44-00
Start: 2021-09-10Target: 1482Updated: 2025-11-25
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib Plus a CDK4/6 Inhibitor and Letrozole Versus Placebo Plus a CDK4/6 Inhibitor and Letrozole in Patients with Endocrine-Sensitive PIK3CA -Mutated, Hormone Receptor-Positive, HER2- Negative Advanced Breast Cancer
RecruitingCTIS2024-516162-11-00
Start: 2025-07-14Target: 176Updated: 2025-11-10